You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Express Scripts
Baxter
Moodys
AstraZeneca
McKinsey
Harvard Business School

Last Updated: February 22, 2020

DrugPatentWatch Database Preview

ERBITUX Drug Profile


Email this page to a colleague

See Plans and Pricing

« Back to Dashboard

Recent Clinical Trials for ERBITUX

Identify potential brand extensions & biosimilar entrants

SponsorPhase
GCS IHFB Cognacq-JayPhase 2
Academic and Community Cancer Research UnitedPhase 2
Jonsson Comprehensive Cancer CenterPhase 2

See all ERBITUX clinical trials

Recent Litigation for ERBITUX

Identify key patents and potential future biosimilar entrants

District Court Litigation
Case NameDate
CELGENE CORPORATION v. DR. REDDY'S LABORATORIES, LTD.2019-07-12
2654 Highway 169, LLC2016-04-13
Reckitt Benckiser Pharmaceuticals Inc. v. Watson Laboratories Inc.2013-10-08

See all ERBITUX litigation

PTAB Litigation
PetitionerDate
GEMoaB Monoclonals GmbH2019-12-20
2018-09-14
2018-01-08

See all ERBITUX litigation

Pharmacology for ERBITUX
Mechanism of ActionHER1 Antagonists

Company Disclosures: US Patents for ERBITUX

These patents were extracted from company disclosures
Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Imclone ERBITUX cetuximab VIAL; INTRAVENOUS 125084 001 2004-06-18   Start Trial Rhone-Poulenc Rorer International (Holdings), Inc. (Greenville, DE) 2018-04-17 RX Orphan company
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Patent Text Search: US Patents for ERBITUX

These patents were identified by searching patent claims

Supplementary Protection Certificates for ERBITUX

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
132016000025345 Italy   Start Trial PRODUCT NAME: TRASTUZUMAB PER USO SOTTOCUTANEO(HERCEPTIN); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/00/145/002, 20130828
91116 Luxembourg   Start Trial 91116, EXPIRES: 20140915
5/2015 Austria   Start Trial PRODUCT NAME: POMALIDOMID UND SEINE PHARMAZEUTISCH AKZEPTABLEN SALZE, SOLVATE, HYDRATE ODER STEREOISOMERE; REGISTRATION NO/DATE: EU/1/13/850 20130805
C20150005 00140 Estonia   Start Trial PRODUCT NAME: POMALIDOMIID;REG NO/DATE: EU/1/13/850 08.08.2013
122008000030 Germany   Start Trial PRODUCT NAME: PANITUMUMAB MIT WENIGSTENS EINEM WIRKSTOFF AUSGEWAEHLT AUS IRINOTECAN, CISPLATIN, 5-FLUOROURACIL, GEMCITABIN, PACLITAXEL UND CARBOPLATIN; REGISTRATION NO/DATE: EU/1/07/423/001-003 20071203
>Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
McKesson
Boehringer Ingelheim
Merck
McKinsey
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.